


## IRAK4-IN-1

|                    |  |       |         |
|--------------------|--|-------|---------|
| Cat. No.:          | HY-101922  |       |         |
| CAS No.:           | 1820787-94-7                                     |       |         |
| Molecular Formula: | C <sub>19</sub> H <sub>23</sub> N <sub>5</sub> O |       |         |
| Molecular Weight:  | 337.42   |       |         |
| Target:            | IRAK   |       |         |
| Pathway:           | Immunology/Inflammation                          |       |         |
| Storage:           | Powder   | -20°C | 3 years |
|                    |  | 4°C   | 2 years |
|                    | In solvent                                       | -80°C | 2 years |
|                    |  | -20°C | 1 year  |



### SOLVENT & SOLUBILITY

|   |   |                          |           |           |            |            |
|---|---|--------------------------|-----------|-----------|------------|------------|
| In Vitro  | DMSO : 14.29 mg/mL (42.35 mM; Need ultrasonic)  |                          |           |           |            |            |
|   |   | Solvent<br>Concentration | Mass      | 1 mg      | 5 mg       | 10 mg      |
|   | Preparing<br>Stock Solutions  | 1 mM                     |           | 2.9637 mL | 14.8183 mL | 29.6367 mL |
|   |   | 5 mM                     |           | 0.5927 mL | 2.9637 mL  | 5.9273 mL  |
| 10 mM   |   |                          | 0.2964 mL | 1.4818 mL | 2.9637 mL  |            |
| Please refer to the solubility information to select the appropriate solvent. |   |                          |           |           |            |            |
| In Vivo   | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline<br>Solubility: ≥ 1.43 mg/mL (4.24 mM); Clear solution |                          |           |           |            |            |

### BIOLOGICAL ACTIVITY

|                           |  |
|---------------------------|--|
| Description               | IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC <sub>50</sub> of 7 nM.  |
| IC <sub>50</sub> & Target | IC <sub>50</sub> : 7 nM (IRAK4) <sup>[1]</sup>   |
| In Vitro                  | The in vitro metabolic stability profiles of IRAK4-IN-1 (Compound 23) is measured, with EC <sub>50</sub> of 2300 nM for the rat whole blood (RWB) <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |
| In Vivo                   | Oral pharmacokinetic studies of IRAK4-IN-1 (Compound 23) show it to have high bioavailability of 73% and low plasma clearance (Cl <sub>p</sub> =22 mL/min/kg) leading to a reasonable half-life of 1.3 h <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

---

## PROTOCOL

### Animal Administration <sup>[1]</sup>

#### Rats<sup>[1]</sup>

In the TLR driven in vivo model, female Lewis rats are dosed with either vehicle or IRAK4-IN-1 (Compound 23; 3, 10, 30, and 100 mg/kg; p.o.) dosed at 1 h prior to stimulation with Resiquimod, R848 (5 mg/kg, IP). At 1.5 h post R848 stimulation, blood samples are obtained from the animals and cytokine levels are measured.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Smith GF, et al. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2721-2726.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA